STIM Neuronetics

Neuronetics to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call

Neuronetics to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call

MALVERN, Pa., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release third quarter financial and operating results prior to market open on Tuesday, November 9, 2021. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

The conference call will be broadcast live in listen-only mode via a webcast on the Company’s investor relations website at . To listen to the conference call on your telephone, please dial (877) 472-8990 for United States callers or +1 (629) 228-0778 for international callers and reference confirmation code 3891687, approximately ten minutes prior to start time. The replay will be available on the Company's website for approximately 60 days.



About Neuronetics



Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Our first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Additional information can be found at . 

Investor Contact:

Mike Vallie or Mark Klausner

Westwicke Partners

443-213-0499

 

Media Contact:

EvolveMKD

646.517.4220

 



EN
26/10/2021

Underlying

STIMNeuronetics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Neuronetics

 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter an...

Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth on an adjusted pro forma basisFull year 2025 revenue of $149.2 million, representing 99% year-over-year growth on an as reported basis and 15% year-over-year growth on an adjusted pro forma basisAchieved positive operating cash flow of $0.9 million in the fourth quarter 2025Ended 2025 with t...

February 10, 2026 1 EN
 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare...

Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference MALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that the management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, Dec. 4, 2025. T...

November 20, 2025 1 EN
 PRESS RELEASE
Free
STIM NEURONETICS

TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Ag...

TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression New Policy Update Brings Innovative, Non-Drug Depression Treatment to Adolescents Across 26 States MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, announced that TriWest, the regional administrator for TRICARE, has updated its medical poli...

November 12, 2025 1 EN
 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics Reports Third Quarter 2025 Financial and Operating Results...

Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of 25% on an adjusted pro forma basis versus Q3 2024 Continued cash management improvement, with cash used in operations of $0.8 million in Q3 2025 Strengthened balance sheet in Q3 2025, ending the quarter with $34.5 million of total cash, consisting of cash, cash equivalents, and restrict...

November 4, 2025 1 EN
 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)...

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to twelve new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as a material inducement to the...

October 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch